Alimera Sciences, Inc. (ALIM): Price and Financial Metrics

Alimera Sciences, Inc. (ALIM): $5.54

0.01 (-0.18%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add ALIM to Watchlist
Sign Up

ALIM Price/Volume Stats

Current price $5.54 52-week high $5.65
Prev. close $5.55 52-week low $2.61
Day low $5.53 Volume 2,679,900
Day high $5.56 Avg. volume 376,318
50-day MA $5.56 Dividend yield N/A
200-day MA $4.18 Market Cap 290.24M

ALIM Stock Price Chart Interactive Chart >


Alimera Sciences, Inc. (ALIM) Company Bio


Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States, Germany, the United Kingdom, and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. It sells its products through direct sales and distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.


ALIM Latest News Stream


Event/Time News Detail
Loading, please wait...

ALIM Latest Social Stream


Loading social stream, please wait...

View Full ALIM Social Stream

ALIM Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2023 N/A
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!